Iterum Therapeutics plc Ordinary Share (ITRM) Dividend History

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing innovative antibiotics for serious and life-threatening infections. The company aims to address the growing problem of antibiotic resistance by creating new therapies to treat resistant bacterial infections. Its pipeline includes oral and intravenous formulations designed to combat multidrug-resistant pathogens.

Fitzwilliam Court, 1st Floor, Dublin 2, L2, D02 YW24
Phone: (872) 225-6077
Website: https://www.iterumtx.com

Dividend History

Iterum Therapeutics plc Ordinary Share currently does not pay dividends

Company News

Iterum Therapeutics Announces Extension of Term of Promissory Note

Iterum Therapeutics announced that Pfizer has agreed to extend the payment deadline for a $20 million regulatory milestone related to the approval of ORLYNVAH, Iterum's oral antibiotic. This extension will allow Iterum to strategically invest any near-term revenue from ORLYNVAH's sales into its successful launch.

GlobeNewswire Inc.

Featured Companies: PFE
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Iterum Therapeutics presented a poster at ECCMID 2025 on the impact of age on antibiotic resistance and efficacy for women with uncomplicated urinary tract infections. The poster highlighted the company's efforts to develop next-generation oral and IV antibiotics to treat multi-drug resistant infections.

GlobeNewswire Inc.
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Iterum Therapeutics received FDA approval for its antibiotic ORLYNVAH™ to treat uncomplicated urinary tract infections. The company has extended its cash runway into the second half of 2025 and is focused on pre-commercialization activities for the new drug.

GlobeNewswire Inc.
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Iterum Therapeutics, a company focused on developing antibiotics to treat drug-resistant infections, will release its Q4 and full-year 2024 financial results on February 7, 2025. The company has received FDA approval for its oral antibiotic ORLYNVAH and has QIDP and Fast Track designations for its oral and IV formulations of sulopenem.

GlobeNewswire Inc.
Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Iterum Therapeutics received FDA approval for its new antibiotic ORLYNVAH™ to treat uncomplicated urinary tract infections. The company is now seeking strategic partners to commercialize the product.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 08:25:50 UTC